Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.33 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.31 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14930895 | 0.80 | FBP1 (0.46) | INPP5A | |
| SCHEMBL17586041 | 0.77 | FBP1 (0.33) | INPP5A | |
| SCHEMBL15492995 | 0.76 | INPP5A (0.39) | INPP5A | |
| SCHEMBL10023962 | 0.76 | INPP5A (0.39) | INPP5A | |
| SCHEMBL19464721 | 0.76 | INPP5A (0.39) | INPP5A | |
| SCHEMBL432511 | 0.76 | INPP5A (0.39) | INPP5A | |
| SCHEMBL481700 | 0.76 | INPP5A (0.39) | INPP5A | |
| SCHEMBL19733299 | 0.75 | PDK1 (0.31) | — | |
| SCHEMBL15492694 | 0.75 | — | — | |
| SCHEMBL12914750 | 0.74 | SMN1; SMN2 (0.34) | SMN1; SMN2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210032283-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS FOR THEIR SYNTHESIS | WAVE LIFE SCIENCES LTD. (SG) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032283-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS FOR THEIR SYNTHESIS | RNGTT, TYMP, POLM | SMN1; SMN2 2143/4885ALDH1A1 4475/4885TDP1 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.